Additionally, it exhibits notable clinical efficacy by alleviating dry eye-related symptoms (as indicated by the OSDI score), enhancing tear film stability (measured by NIBUT, NIAvg-BUT, OSS, Schirmer’s test, and meibomiography), and exerting an anti-inflammatory effect (evidenced by the reduction in the MMP-9 positivity rate and the normalization of CIC) in patients afflicted with mild-to-moderate DED. This evidence concerns the gene MMP9 and dry eye syndrome.